RVL Pharmaceutical’s Upneeq Eye Drops Wins 2021 Allure Best of Beauty Breakthrough Award

RVL Pharmaceutical’s Upneeq Eye Drops Wins 2021 Allure Best of Beauty Breakthrough Award

November 17, 2021

RVL Pharmaceutical’s Upneeq eye drops, which temporarily lift low-lying eyelids, won a 2021 Best of Beauty Breakthrough Award by Allure Magazine.

Upneeq is a prescription eye drop that has been approved by the FDA for the treatment of acquired blepharoptosis (low-lying lids) in adults. Before Upneeq, correction surgery was the sole option for people with ptosis who wanted to truly lift their eyelids.

Upneeq is able to temporarily lift a patient's lid with just one drop (average lift in clinical trials was 1mm with some patients experiencing lift up to 3mm).

It can make a significant difference for patients with acquired ptosis, changing the game for eye care specialists looking to give comprehensive care to their patients.

Allure editors view clinical data and gather solicit feedback from outside judges in order to assess the product's quality and determine whether it is genuinely a breakthrough.

Of the 2021 winners, Allure wrote, “We present seven of the most revolutionary innovations we've ever seen — ones that have changed the way we approach beauty. These new products boggled our editors' minds and forever changed our beauty routines.”

“We are grateful to receive this important award and excited that the ground-breaking innovation in Upneeq is being recognized,” said Dr. Ray Douglas, an aesthetic reconstructive and oculoplastic specialist and Global Head of Scientific Affairs for RVL Pharmaceuticals. “Until Upneeq, there was no pharmacologic treatment on the market. RVL is passionate about continuing to provide novel solutions for both vision and aesthetics.”

Upneeq (0.1% oxymetazoline hydrochloride ophthalmic solution) works by triggering the levator muscle, which contracts and lifts the eyelid. The dosage is one drop a day per affected eye.

Some patients reported seeing a difference in as little as five minutes in early studies, with complete responses taking two hours.

“Millions of Americans may suffer from an often undiagnosed or overlooked condition called ‘acquired blepharoptosis,’ also known as acquired ptosis or ‘droopy eyelids’,” says Dr. Douglas. “The condition not only affects the aesthetics of the face, but may also cause vision impairment that interferes with day-to-day functions such as reading and driving. We are excited to offer a noninvasive option to increase eyelid lift.”

Visit Upneeq to learn more about the award-winning drops. See below for Important Safety Information.

To read the Allure 2021 Best of Beauty Breakthrough Awards article, click here.